|Mr. Neil F. McFarlane||CEO & Director||784.85k||N/A||1973|
|Mr. Christopher B. Prentiss||Chief Financial Officer||549.47k||N/A||1975|
|Mr. Vijay Shreedhar Ph.D.||Chief Commercial Officer||685.89k||N/A||1971|
|Ms. Sarah Mathieson||Head of Corp. Communications, Patient Advocacy & Engagement||N/A||N/A||N/A|
|Mr. Dean Hart||Sr. VP of Sales||N/A||N/A||N/A|
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Adamas Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 7, 2019 is 7. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 8; Compensation: 9.